DRI Capital to float pharma royalties fund in London

By Aidan Gregory
12 Feb 2020

Canada’s DRI Capital is preparing to list a new fund on the London Stock Exchange focused on investing in pharmaceuticals royalties.

In an intention to float document, DRI Healthcare, as the new closed end fund will be known, said it would raise $350m by selling new shares to institutional investors. Jefferies is global co-ordinator, Numis Securities is bookrunner and sponsor.

The proceeds of the transaction will be used to ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial